

Senseonics

Investor Presentation

November 2026

Disclaimer

This presentation has been prepared by Senseonics Holdings, Inc. (the "Company," "Senseonics," "we," "us") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding expectations for future financial or other performance including projected revenue, gross margin, earnings and EBITDA growth, the Company's future financial profiles, statements regarding plans, objectives and goals for future operations, statements about the future growth of Eversense® products, statements regarding planned initiatives, investments or marketing or other programs of Senseonics, statements regarding progress and timing of collaboration and/or product integration and rate of adoption or growth with respect to Eversense, or its patients, the EON Care network and/or providers, or the potential to enhance patient outcomes, statements regarding increasing patient access, adoption and market share, and the future growth of the CGM market, statements regarding financial capacity, accretion, and funding of growth, statements regarding advancing and timelines for development programs and potential regulatory events, approvals, coverage and availability and the attributes of future products, including launch timing of Gemini and Freedom, features, attributes and integrations, and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned" and similar expressions constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and projections about future events, and such statements are, by their nature subject to risk and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including uncertainties inherent in: risks and uncertainties related to demand, adoption, reimbursement, sales mix and costs affecting revenue and gross margins; the Company's ability to expand its commercial infrastructure and achieve the anticipated benefits of its commercial initiatives; risks related to the continued commercial transition and roll-out of Eversense 365 in Europe, including the timing of tender updates; uncertainties in insurer, regulatory, tender authority, health system, and administrative processes and decisions; uncertainties in clinical development, regulatory review, and successful commercialization of new technology and solutions, including Gemini and Freedom, including uncertainties resulting from the Company's dependence on third parties within the Company's development programs and supply chain; uncertainties in completing integrations, satisfying applicable requirements and coordinating with collaboration partners and other third parties; uncertainties inherent in the ongoing commercialization and expansion of Eversense and Senseonics' and its partners' activities; uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs; and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2025 and quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors."

In addition, the forward-looking statements included in this presentation represent Senseonics' views as of the date hereof and the delivery of this presentation at any time shall not under any circumstances create an implication that the information contained herein is correct as of any time after such date. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. This presentation also presents management's goals and vision for Senseonics development programs, including without limitation the Gemini and Freedom development programs. These products are not approved by the FDA and the Freedom product is not subject to an IDE or other investigational approval. Plans, timing, specifications and other details of these programs are subject to change based on the factors above. The forward-looking statements in this presentation should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

About Eversense 365

Eversense® 365 is the only long-term continuous glucose monitoring (CGM) system available, offering people with diabetes a truly differentiated CGM experience. Designed for people with diabetes who demand more, Eversense 365 combines a small sensor inserted under the skin by a healthcare provider with a removable smart transmitter that delivers real-time glucose data to a mobile app or an integrated Automated Insulin Delivery (AID) system. With a single sensor designed to last a full year, Eversense 365 provides a unique approach to CGM that supports health outcomes, enhances patient confidence, and minimizes the burden associated with short-term devices.

Eversense 365 is cleared in the U.S. and approved in Europe for people with diabetes aged 18 years and older, and is available by prescription only. The system is indicated for continually measuring glucose levels for up to 365 days, and for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions (fingerstick BG measurements are still required for calibration primarily one time per week after day 14, and when symptoms do not match CGM information or when taking medications of the tetracycline class). It is available in the U.S. and in select European markets. Patients should talk to their health care provider to learn more. For important safety information, visit https://www.eversensecgm.com/safety-information/.

Senseonics.

Redefining CGM.

Disruptive Technology

Evolving Business

Focused Strategy

Commercial Momentum

Clear Roadmap



Senseonics®

Investment *Highlights*

Disruptive Technology
Eversense 365 is the world's first and only one year CGM. It is designed for people with diabetes who demand more, offering a truly differentiated CGM experience

- #1 longevity and expanding AID availability
- Validation from peer-reviewed real-world evidence

Evolving Business
An enhanced financial profile and energized the team continues to unlock potential and accelerate growth

- Integration complete and driving record growth
- Topline accretion and margin expansion

Focused Strategy
Executing a clear growth strategy that drives pioneering R&D and commercial excellence, with a focus on awareness, access, penetration and retention

- Investing for growth with significant capital raised
- On track for ambitious commercial targets

Commercial Momentum
More people than ever are choosing Eversense 365, with consistent growth validating our commercial strategy and our focused investment

- Q3 2026 revenue growth of 140% (YoY)
- Record revenues the second successive quarter


Clear Roadmap
Building a sustainable financial profile as we advance a game-changing innovation pipeline expected to revolutionize diabetes care

- Raised FY revenue guidance to $68-$70M from $62-$66M
- First-in-human study initiated for Freedom

Redefining CGM: *We Approach Diabetes Differently*

Disrupting a large and growing market, dominated by products with similar limitations

Global CGM Market Size



Common CGM Frustrations

Early failures
Accuracy issues
Wasted sensors
Skin irritation
Compression lows
Alarm fatigue

**Medtech Market Intelligence Report: CGM Market Mass Device (October 2025)*

eversense 365 Continuous Glucose Monitoring System — The world's first and only One Year CGM

- Longest Lasting CGM
- Industry-Leading Survivability
- Exceptional Accuracy
- Eliminates Short Term Sensor Waste
- Minimal Skin Irritation
- Reduced Compression Lows




Product claims on this slide are derived from sources on file at Senseonics and user manuals of competitor products

Designed For People Who *Demand More* From Their CGM

People deserve choice. Our unique approach is redefining CGM and minimizing daily frustrations caused by short-term devices

	Dexcom G7 15 DAY [1]	Libre 3 PLUS [2]	eversense 365 [3]
Sensor lifetime	15 days	15 days	365 days
Sensor survivability	73.9%	83.1% adults 76.8% peds	93.4%
Compression lows	Yes	Yes	None
Accuracy in low glucose ranges*	12.5	15.5	7.7
CGM changes per year	36	24	1
Low glucose events detected†	76%	76%	91%

NEW EVERSENSE USERS



1. FDA 510K Decision Summary –Dexcom G7 15 Day
2. FDA 510K Decision Summary –Abbott Libre 3 plus
3. Senseonics. (2026) Eversense 365 Continuous Glucose Monitoring System User Guide. LBL-7702-01-001

* <54mg/dL(MAD in mg/dL)
† at 60 mg/dL
Source (new user switching): Senseonics internal data

Improving Patient Choice and Access with *AID Integration*

Eversense 365's unique form factor and features make it well-suited to AID system integration

SUPPORTING A NEW PATIENT SEGMENT

- Integration with Sequel's twiist™ AID System is available now in the US, with encouraging early uptake and patient impact*.
  - The twiist™ pump is now approved for Type 2 diabetes
- New partnership with Beta Bionics and expected launch with iLet® Bionic Pancreas in Q4'26. Integration also planned with Mint™, Beta Bionics' recently FDA-approved patch pump
- Continued focus on maximizing AID-system interoperability, which is a significant growth opportunity for 2027 and beyond, providing opportunity for additional T1D uptake

twiist™ + eversense 365 + Beta Bionics



*Real-World Data from U.S. Commercial Users of the 365-Day Implantable Eversense Continuous Glucose Monitoring System, Including with the Twiist Automated Insulin Delivery System Integration. Kaufman FR, Jain I, Han S, Mdingi C. Diabetes Technology & Therapeutics. 2026;0(0). DOI: 10.1177/15209156261486125.

Proven *Real-World Outcomes* Across Both Use Cases

Real-world evidence from ADA published in the peer-reviewed journal, *Diabetes Technology & Therapeutics,* highlighting proven high adherence and sustained favorable glucometrics over one year with Eversense 365[1]

OPEN-LOOP THERAPIES

WEAR TIME AND GLYCEMIC RESULTS SUSTAINED ACROSS 365 DAYS

12,360 sensors

12 months

93% median transmitter wear time

7.16% mean GMI*

66.2% mean time in range

>80% hypoglycemic targets met [2]

Comparable data for first and second six-month of wear

High Adherence

Sustained Performance

Strong glycemic results

AID SYSTEM INTEGRATION

PRELIMINARY DATA SHOWED PROMISING RESULTS

153 sensors

≥30 days

99% median transmitter wear time

6.78% mean GMI*

76.1% mean time in range


>80% hypoglycemic targets met [2]


1. Real-World Data from U.S. Commercial Users of the 365-Day Implantable Eversense Continuous Glucose Monitoring System, Including with the Twiist Automated Insulin Delivery System Integration. Kaufman FR, Jain I, Han S, Mdingi C. Diabetes Technology & Therapeutics. 2026;0(0). DOI: 10.1177/15209156261486125.
2. Battelino T, Danne T, Bergenstal RM, et al. 2019;42(8):1593-1603. doi:10.2337/dci19-0028


* Glucose management indicator


Translating Patient Impact into *Growth*

Senseonics is delivering record growth following a successful commercial integration, raising 2026 revenue guidance to $68M–70M and 140% YoY with Q3 results









Growth supported by Senseonics' evolution into an end-to-end diabetes company

Unlocked *operational* efficiencies

Accelerated *commercial* execution

Enhanced our *financial* profile

A *Focused Commercial Strategy* That is Working

We have raised significant growth capital to continue to scale. Strong momentum is validating our commercial strategy and we are on track for ambitious growth targets

1

Awareness

DTC marketing

HCP marketing

Optimize targeting and product positioning

2

Access

Expand and optimize our inserter network (incl. our in-house EON Care network)

Further expand coverage

Enhance patient affordability

3

Penetration

Expand commercial team and capacity

Drive commercial growth in our four European markets

AID* market expansion

4

Retention

Refine onboarding process

Enhance user experience

Provide proactive support, with focus on renewals

Supported by gaining control of commercial functions, successfully launching Eversense 365 across select European markets, and improving financial firepower with $112M+ growth capital

Senseonics®

*Automated insulin delivery systems.

Our *Commercial* Approach

U.S. Channel Conversion Funnel



Focus on generating high-quality leads, increasing reachability and efficient conversion

DTC Channel
~60% new patients
60 reps
DTC spend of $13-15M

HCP Channel
~40% new patients
50 reps
43 US territories

Submit Leads & Identify and Reach Out to Workable Leads

Convert to Opportunity

Convert to Shipments

Reorders
Patient renewals are a crucial third sales channel

European Launch

Eversense 365 is available in four EU markets with ~60 Senseonics employees in the region



Tender market



Non-tender market



Tender market



Tender market

Senseonics®

Expanding Access with *EON Care*

Our growing in-house network of mobile healthcare providers is significantly expanding access across the U.S., increasing insertion convenience nationwide

- Extends reach to untapped patients
- Enables prescriber-only physicians
- Boosts field-sales efficiency
- Centralized scheduling & patient training
- Reimbursable path to self-funding

Our ongoing priorities:

1. Activate More Inserters

Exceeded target of 100 nurses by the end of 2026

Increased target by 20% to a total of 120 by year end

2. Commercial Optimization

Leaning into EON for growth and scale

EON is <10% of all inserters but handles ~40% of insertions

Our Journey is *Just Getting Started*

Our long-term implantable technology is redefining CGM today and we continue to innovate to transform the patient experience for tomorrow

Yesterday → Today → Tomorrow



Short-term CGM

Traditional CGMs were an important step from BGM



Long-term CGM

Eversense 365 offers a truly differentiated CGM experience



Invisible CGM

A game-changing R&D pipeline that can make this a reality*

Senseonics®

*Program in development. Subject to risks and uncertainties. For more information, see "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent filings with the SEC.

Our Innovation Ethos and *Game-changing Pipeline*

Senseonics is not interested in incremental innovation. We are pushing the boundaries of sensing technology to make diabetes less visible and transform lives in the community

VISION


A portfolio of year-long sensors that have no on-body components and support all patient segments

Driven by what patients want

Eversense 365

Gemini

Freedom




Evolving validated technology

We have a strong track record of innovation and engineering excellence. Through our R&D team we have created an entirely new category of long-term implantable CGMs, the world's first one-year CGM and are now working to make CGM invisible

Senseonics®

Our Most *Transformative* Opportunity

First-in-human studies are now underway for Freedom – designed to be the world's first CGM with no required on-body component



Enhanced Eversense 365 sensor

Integrated 1-year battery

Integrated Bluetooth capability

Exciting value proposition for millions of people with diabetes

Q2 2026 ✓
Animal study lays the foundation for first-in-human

Q3 2026 ✓
Initiate first-in-human clinical study

H1 2027
IDE submission

Mid-2027
Initiate pivotal study of BLE communication

Early 2028
510(k) submission

Mid-2028
Potential commercial launch

Senseonics®

Program in development. Product attributes, specifications, and development progress and timelines subject to risks and uncertainties. For more information, see "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent filings with the SEC.

Redefining CGM *Today and Tomorrow*

Awareness and uptake of Eversense 365 is greater than ever and our innovation pipeline will build on this platform. We are delivering real-world impact today and have set out a clear future vision

REDEFINING THE CGM EXPERIENCE TODAY

"Eversense 365 is the first technology I've ever used that truly made it feel like I could take a break from my diabetes.

The only regret I have is that I didn't get Eversense 365 sooner... in my opinion, this is the best CGM on the market.

Eversense365 has completely changed the way I manage my diabetes.

I have tried to tell as many people as I can about Eversense and how it has impacted my life in the most positive ways possible.

Most of my patients come back for reinsertion the following year, which means they are happy too

I can't wait until next year and my next sensor... it's essential for my best life"

GROWING EXCITEMENT FOR NEXT CHAPTER



There is enthusiasm about Eversense 365 and the future pipeline for Senseonics

Q3 Performance and Business *Highlights*

Q3 FINANCIAL INFORMATION

REVENUE	$19.6M	+140% YoY
GROSS PROFIT	$12.1M	+245.7% YoY
GROSS MARGIN	62%	v. 43% in Q3 '25
CASH (as of 9/30/26)	$126.6M	v. $64.6M in Q1 '26

Q3 BUSINESS HIGHLIGHTS

- U.S. commercial momentum; revenue grew more than 140% YoY
- Record quarterly shipment volume in company history
- Active prescribers up approximately 90% YoY
- Scaled EON Care past full year target of 100 nurses and raised target to 120; approx. 40% of Eversense Q3 insertions
- Delivered the first quarter of ex-US sales following transition of the European commercial operations; up 65% YOY
- Validating real-world evidence published in peer-reviewed journal
- Initiated first-in-human study of Freedom invisible CGM

Senseonics®

** Cash, restricted cash and cash equivalents*

Eversense U.S. Revenue Streams

Sales Channels

DTC CHANNEL
Social Media & Digital Advertising

Patient leads via targeted social campaigns and digital platforms → scheduling workflow

HCP CHANNEL
Field Sales Representatives

Physician leads via sales reps → office implantations and CDM engagement

REORDERS
Patient Renewals

Existing patients retained on Eversense feed back into both reimbursement channels

Reimbursement Channels

DME CHANNEL
Distributors with Insurance Payor Contracts

40%
of volume

BUNDLED PAY (BP)
Product + Procedure Fee

60%
of volume

★ **Notably higher ASP**
Bundled Pay ASP meaningfully exceeds DME channel ASP

Revenue Streams

DISTRIBUTOR

Direct to Distributor (DME)

Product Revenue Only

Insurance contracts held by distributor

EON CARE — Commercial

Commercial Payors

Product + Procedure Revenue

Contracted through EON Care; commercial insurance payor network

EON CARE — Medicare

Medicare

Product + Procedure Revenue

Medicare reimbursement via EON Care platform

CONSIGNMENT

Bundled Pay Physicians

Product Revenue Only

Inventory held at physician; revenue recognized on use

Senseonics®

Building a *Sustainable* Financial Profile

Well-positioned to reach our target of long-term profitability

Where we are today (Q3 2026)

Completed integration of commercial operations

$19.6M revenue – *+140% year-over-year growth*

62% gross margin – *Compared to 43% in Q3 2025*

$126.6M cash, restricted cash and equivalents

$112M+ growth capital raised

Continued investment in growth for 2026 into 2027

Raised guidance again for FY 2026

$68M–$70M revenue
Projected YoY growth of 93%–98%
Seasonality: ~40% H1 / ~60% H2

More than 60% gross margin

Our target profile

Sustainable earnings growth

70%+ gross profit margin

EBITDA breakeven and profitability

Self-funded R&D pipeline

Product portfolio – Freedom launch 2028

Multiple pump partnerships

Realizing near-term revenue

Expanding topline growth

Achieving scale and profitability

Experienced Management Team



Timothy Goodnow

President & Chief Executive Officer

VERAX BIOMEDICAL

THERASENSE The Technology of Caring

Abbott Diabetes Care

DADE BEHRING

Baxter



Brian Hansen

Chief Commercial Officer

TANDEM Diabetes Care

ASCENSIA Diabetes Care



Francine R. Kaufman

Chief Medical Officer

NDEP National Diabetes Education Program

American Diabetes Association.

Medtronic



Rick Sullivan

Chief Financial Officer

RoosterBio®

HIKE FINANCIAL



Mukul Jain

Chief Operating Officer

Medtronic

Q&A.

Redefining CGM.

Disruptive Technology

Evolving Business

Focused Strategy

Commercial Momentum

Clear Roadmap



Senseonics®